Tolera Therapeutics closes Series B-3 financing, raises $5.5 million to submit Phase 3 Special Protocol Assessment for its immune targeting biologic drug in kidney transplantation

KALAMAZOO, Mich., Oct. 16, 2012 — /PRNewswire/ – Tolera Therapeutics Inc., a privately held biotechnology company focusing on the development of immunotherapeutics directed at the transplantation, autoimmune and oncology markets, announced today that it has closed […]

Read On ›

Tolera Therapeutics Announces Appointment of Linda C. Hogan as Vice President, Business Development

KALAMAZOO, Mich., Oct. 1, 2012 – /PRNewswire/ – Tolera Therapeutics, Inc., a privately held biotechnology company focused on the development of immunotherapeutics directed at the transplantation, autoimmune and oncology markets announced today the appointment of Linda C. […]

Read On ›